Science Daily3d
Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Vietnam Investment Review on MSN2d
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from ...
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...
Targeted Oncology3d
FDA Fast Tracks Amezalpat for HCC Treatment
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Monthly Prescribing Reference4d
Amezalpat Gets Fast Track Status for Hepatocellular Carcinoma
Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.
Nasdaq4d
Tempest Therapeutics' Amezalpat Receives FDA Fast Track and Orphan Drug Designations for Hepatocellular Carcinoma Treatment
Tempest Therapeutics, Inc. announced that the FDA has granted Fast Track Designation to amezalpat (TPST-1120), an oral small molecule designed to treat hepatocellular carcinoma (HCC), recognizing ...
Daily7d
Hepatocellular Carcinoma After Hepatitis C Cure: Study Emphasizes The Need for Long-Term Surveillance
China: A recent study published in the Annals of Hepatology has emphasized the influence of age on hepatocellular carcinoma ...
Business Insider4d
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma (HCC). “We are thrilled to receive Fast Track designation from the FDA,” said Sam Whiting, M.D., Ph.D ...
ascopubs.org18d
Long-term survival outcomes of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma.
Efficacy and safety of HER2-targeted therapies in biliary tract cancer: A systematic review and meta-analysis of early phase clinical trials. 3-year, 4-year and 5-year OS rate of patients who receive ...